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Received September 19, 2012; accepted January 14, 2013AbstractBackground: In recent years, there has been increasing interest in the role of plasma homocysteine (Hcy) as a possible risk factor for several
diseases of the central nervous system. The aim of this study was to determine the plasma levels of Hcy in a group of multiple sclerosis (MS)
patients from a Greek population and the possible correlation with age, disability status, activity or duration of disease, sex, and treatment.
Methods: The MS group that was studied consisted of 46 patients and a total of 42 healthy individuals served as a control group. Plasma Hcy
levels were determined by means of high-performance liquid chromatography coupled with fluorescence detection, after precolumn derivati-
zation with 4-Fluoro-7-aminosulfonylbenzofurazan (ABD-F).
Results: Statistical analysis revealed that, in the MS patients, Hcy levels were not significantly different as compared to those in the controls.
Men presented with higher Hcy levels than women in the MS group; however, age, disease subtype, disease duration, relapse rate, and Expanded
Disability Status Scale score/Multiple Sclerosis Severity Score did not significantly affect Hcy levels in MS patients.
Conclusion: The preliminary data suggest that Hcy levels were not elevated in our sample of Greek MS patients, which does not support previous
findings of a significant correlation between elevated serum Hcy levels and MS. Further studies to establish a possible association between MS
and Hcy levels in the context of different ethnic groups with different habits are needed.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Homocysteine (Hcy) is a sulfhydryl-containing amino acid.
Methionine in food is demethylated to Hcy, which is further
processed to cysteine, or remethylated to methionine. However
abnormalities in this pathway may cause increased Hcy levels.
It has been suggested that increased plasma Hcy levels may be
an important yet potentially treatable risk factor, or a
contributor to the mechanisms of several neurological diseases
including multiple sclerosis (MS).1,2 Several recent studies
found elevated plasma Hcy levels in patients with MS, but* Corresponding author. Dr. Evangelia Kararizou, Neurologic Clinic, Aigi-
nition Hospital, 72e74, Vassilisis Sofias Avenue, 11528 Athens, Greece.
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http://dx.doi.org/10.1016/j.jcma.2013.07.002another found no significant difference in plasma Hcy con-
centrations between patients with MS and controls.3e5 Ac-
cording to the 2003 study of Vrethem et al, the increased
plasma Hcy levels in MS patients are not generally associated
with vitamin B12 deficiency.6 In the present study we deter-
mined the plasma levels of Hcy in a group of MS patients from
the Greek population and investigated a possible correlation
with age, disability status, disease activity, disease duration,
sex, and treatment.
2. Methods2.1. PatientsThis study was approved by the local ethics committee of
our hospital and performed according to the ethical standardshinese Medical Association. All rights reserved.
Table 1
Demographic and biochemical data of studied groups.
Control MS p
n (M/F) 42 (21/21) 46 (14/32) NSc
Age (y)a 35.8  10.3 34.2  9.2 NSd
Hcy (mM)b 10.8 (8.1e13.7) 11 (9e13) NSe
F ¼ female; Hcy ¼ homocysteine; M ¼ male; MS ¼ multiple sclerosis;
NS ¼ not significant.
a Mean  standard deviation.
b Median (25the75th percentile).
c Yates’ continuity corrected c2 test.
d t test.
e Analysis of covariance with diagnostic group and sex as factors and age as
covariate.
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patients. Patients with depression or other psychiatric or
pathological conditions were excluded. All patients had MS
according to the revised McDonald criteria.7 Twenty-one
(45.7%) patients had the relapsingeremitting form of MS,
five (11%) the secondary progressive form, five (11%) the
primary progressive form, and the remaining 15 (32.6%) had a
clinically isolated syndrome with multiple lesions on magnetic
resonance imaging and abnormal cerebrospinal immunoglob-
ulin G index and/or oligoclonal bands (all of them developed
MS within the next 2 years). The mean (standard deviation)
age onset was 30 ( 8) years and mean (standard deviation)
disease duration was 5.5 ( 4.7) years (range 0.1e22 years).
Median (25the75th percentile) Expanded Disability Status
Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS)
were 2 (1.5e3.5) and 4.2 (2.6e7.3), respectively. In patients
experiencing relapse, the median relapse rate was 0.8 (range:
0.2e2). Twenty (43.5%) patients were at relapse when blood
samples were obtained.
It was our purpose to study as many treatment-naı¨ve pa-
tients as possible. Thus, in 36 patients (78%), blood sampling
was performed prior to treatment was initiated, and only nine
patients were already on interferon or other immunomodula-
tory treatment. The control group consisted of 42 healthy in-
dividuals of comparable age from the Greek population. None
of the patients and controls had abnormal B12 or folate levels,
and none reported using vitamin supplements in the past
2 years.
Plasma Hcy level were measured by high-performance
liquid chromatography with precolumn derivatization and
fluorescence detection (excitation 385 nm, emission 515 nm)
by the use of a commercial kit (Homocysteine in serum/
plasma; Chromsystems GmbH, Mu¨nchen, Germany).2.2. Statistical analysisTable 2
Relation between Hcy level and clinical parameters in MS patients.
b p
Age (y) 0.113 0.267
Disease duration (y) 0.017 0.489
EDSS score 0.003 0.986
Age of onset (y) 0.084 0.556
Annual relapse rate 0.119 0.516
EDSS ¼ Expanded Disability Status Scale; Hcy ¼ homocysteine;
MS ¼ multiple sclerosis.All variables were checked for normality and equality of
variances by the ShapiroeWilk’s and Levene’s tests, respec-
tively. Hcy levels did not follow the normal distribution and
data are presented in terms of median values and quartiles.
However, logarithmic transformation restored the violation
and permitted the use of analysis of covariance (ANCOVA).
Age and sex have been observed to affect Hcy levels in normal
individuals, therefore, a general factorial two-way ANCOVA
model with diagnostic group and sex as factors and age as a
covariate was used.8 Effects of sex, age, disease subtype,
relapse rate, EDSS/MSSS and the presence or absence of
relapse or treatment were also tested in the MS group by
ANCOVA models and with multiple regression separately in
the control and MS groups. The t test, c2 test, and Spearman’s
rank correlation coefficient were also used as appropriate.
3. Results
The results are summarized in Tables 1 and 2 and Figs. 1
and 2. For comparison between the MS and control groups,
ANCOVA revealed no significant effect of the diagnosticgroup (Fig. 1A) or age; however, sex did affect the model
significantly with men showing significantly higher Hcy levels
than women (F ¼ 31.78, df ¼ 1, p < 0.00001). Men presented
with higher Hcy levels than women in both the MS (F ¼ 7.45,
df ¼ 1, p ¼ 0.01 and control groups (F ¼ 13.75, df ¼ 1,
p ¼ 0.00065; Fig. 1B and C). Age, disease subtype, presence
or absence of relapse or treatment at the time of blood sam-
pling, disease duration, age at disease onset, relapse rate, and
EDSS/MSSS did not affect significantly Hcy levels in MS. In
the control group, male age did not affect Hcy levels signifi-
cantly (Table 2, Fig. 2).
4. Discussion
In recent years, there has been an increase in interest in the
role of plasma Hcy as a possible risk factor for several diseases
of the central nervous system. Hyperhomocysteinemia is
common in Alzheimer’s disease, vascular dementia, and
Parkinson’s disease, particularly after L-dopa treatment.1,2,9,10
Increased Hcy results in increased levels of proin-
flammatory cytokines such as tumor necrosis factor-a, inter-
leukin (IL)-1b and IL-6, prostaglandin E2 and chemokine CC
ligand 2 (monocyte chemoattractant protein-1) in both the
central nervous system and serum and nuclear factor-kB/p65
subunit in the central nervous system.11 Conversely, inflam-
mation and activation of astrocytes by IL-1b and tumor ne-
crosis factor-a resulted in increased levels of Hcy, whereas
Hcy-induced endoplasmic reticulum protein may be involved
in inflammatory mechanisms and autoimmunity.12,13
Several studies have found increased plasma Hcy levels in
MS patients.4e6 Besler and Comoglou14 reported elevated
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Fig. 1. Homocysteine levels in the multiple sclerosis and control groups (horizontal bars indicate medians).
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compared to healthy controls. According to Ramsaransing
et al,4 elevated plasma Hcy occurs in both the benign and
progressive disease course of MS. They noticed that there
were no differences in plasma Hcy concentrations between the
three MS subgroups. The purpose of the recently published
study by Triantafyllou et al15 was to investigate plasma Hcy
levels in patients with MS and depression. They found
significantly increased plasma Hcy levels in MS patients with
depression compared to the controls. In conclusion, the au-
thors suggested that the moderately disabled MS patients with
increased Hcy are particularly prone to develop depressive
symptoms. Contrary to the above findings, the results of the
present study indicate that, in MS patients without depression
or other psychiatric disorders, plasma Hcy levels are not
elevated, leading to speculation that Hcy may not participate
in the pathogenetic mechanisms of MS; at least not in the
population studied. There is also another study by Rı´o et al3
reporting no significant difference in plasma Hcy concentra-
tions between patients with MS and controls. Teunissen et al16
investigated serum Hcy levels in patients with MS andA
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Fig. 2. (A) Homocysteine levels in the no treatment and treatment groups of pat
indicate medians).compared the results between MS subtypes, but the levels
were not elevated in patients with MS compared with controls.
The authors discussed the question of whether Hcy has a direct
impact on MS, or reflects a more general neurodegenerative
process.
Hcy has been considered as a marker for vitamin B defi-
ciency,17 and vitamin B12 is important for myelination of the
central nervous system. An association between vitamin B12
deficiency and MS has been reported.18 However, in their
study, Vrethem et al6 concluded that B12 deficiency, in gen-
eral, is not associated with MS.
Plasma Hcy levels may show some variation according to
the nutritional habits of the studied population, especially B12
and folate intake, therefore, it is possible that different results
may be found in different geographic areas and different
ethnic groups.19,20
The studies that found elevated Hcy levels appear to have
originated from northern countries including Sweden, The
Netherlands, and the United Kingdom, whereas our data are
in accordance with the results from Spain. The report of
Cappuccio et al21 indicates that South Asian Hindus haveRR PP/SP
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ients. (B) Homocysteine levels in different disease subtypes (horizontal bars
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not exclusively) due to their vegetarianism. By contrast, peo-
ple of African origin tend to have lower levels of tHcy than
whites. Czajkowska et al, 22 correlating their results to the
dietary habits in young healthy Polish men, concluded that
habitual daily intake of protein and consequently methionine
has a beneficial effect on plasma Hcy levels. In addition, it
seems feasible that the protein effect on plasma Hcy is due to
the action of methionine and protein-originating vitamins.
All of the patients enrolled in the present study were of
Greek origin, who generally followed the Mediterranean diet,
thus, it is possible that a well-preserved nutritional status
prevented a rise in plasma Hcy.23,24
As mentioned earlier, men presented with higher Hcy levels
than women in our study, which is contrary to the predomi-
nance of female sex in MS. However, the phenomenon of
higher Hcy levels in men is well established and may play a
role in the increased cardiovascular risk found in men.25
However, the increased levels of Hcy in men cannot be
explained by differences in folate and B12 levels alone. Other
factors may be involved, including increased demethylation of
methionine associated with higher creatinine production in
men, which may be influenced by sex hormones.26
In our study, clinical variables such as disease subtype,
presence or absence of relapse or treatment at the time of
blood sampling, disease duration, age at disease onset, relapse
rate and EDSS/MSSS did not significantly affect Hcy levels in
MS. This is in agreement with the findings of Ramsaransing
et al,4 who reported no difference in Hcy levels between MS
patients with a benign and those with a progressive disease
course.
In conclusion, the findings in our sample of the Greek
population do not support previous studies that showed a
significant correlation between elevated serum Hcy levels and
MS. Further studies to establish the possible association be-
tween MS and Hcy levels in the context of different ethnic
groups with different habits are needed. Additionally, the
connection between MS and depression as a potential factor
for elevation of serum Hcy must be further investigated.References
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